Company: DNLI
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001714899-25-000170
Chunk: 193

Company: Denali Therapeutics Inc.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 1
Chunk 193
---
 are summarized in the tables below (in thousands):June 30, 2025Amortized CostUnrealized Holding GainsUnrealized Holding LossesAggregate Fair ValueShort-term marketable securities:U.S. government treasuries$719,188 $1,014 $(71)$720,131 Corporate debt securities37,498 116 — 37,614 Total short-term marketable securities756,686 1,130 (71)757,745 Long-term marketable securities:U.S. government treasuries66,664 188 — 66,852 Corporate debt securities11,568 43 — 11,611 Total long-term marketable securities78,232 231 — 78,463 Total$834,918 $1,361 $(71)$836,208 December 31, 2024Amortized CostUnrealized Holding GainsUnrealized Holding LossesAggregate Fair ValueShort-term marketable securities:U.S. government treasuries$627,809 $1,618 $(27)$629,400 Corporate debt securities21,337 62 — 21,399 Commercial paper6,572 — — 6,572 Total short-term marketable securities655,718 1,680 (27)657,371 Long-term marketable securities:U.S. government treasuries334,300 788 (196)334,892 Corporate debt securities24,354 127 — 24,481 Total long-term marketable securities358,654 915 (196)359,373 Total$1,014,372 $2,595 $(223)$1,016,744  As of June 30, 2025 and December 31, 2024, some of the Company's marketable securities were in an unrealized loss position. The Company has not recognized an allowance for credit losses as of June 30, 2025 or December 31, 2024. The Company determined that it had the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery. Further, a majority of these marketable securities are held in U.S. government securities, and the remainder were initially, and continue to be, held with investment grade, high credit quality institutions. All marketable securities with unrealized losses as of each balance sheet date have been